Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

News Conference News TCT 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

October 09, 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

News Conference News TCT 2019

Long-term PARTNER 2A Results Put Spotlight on Paravalvular Leak in TAVR

September 29, 2019

TCT Live Blog Day 2

News Opinion Editor's Corner TCT 2019

TCT 2019 Day Two: Transcatheter Valves, New and Old

September 27, 2019

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

November 08, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

November 02, 2016

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

Presentation TCT 2014

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Ariel Finkelstein, Vinod H. Thourani

September 13, 2014

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presentation TCT 2013

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presenter: Jodi Akin

October 30, 2013

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Presentation TCT 2013

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Presenter: Martin Leon

October 27, 2013

Update from the Randomized PARTNER 2A Trial

Presentation TCT 2012

Update from the Randomized PARTNER 2A Trial

Presenter: Martin Leon

October 22, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.